Biomarkers for the classification diagnosis of anxiety depressive disorder and applications thereof
By detecting differential expression of IL-17R protein in plasma, protein chip technology was used to achieve accurate screening and subtype classification diagnosis of anxiety-related depression, solving the problem of misdiagnosis of anxiety-related depression in existing technologies and improving the accuracy of diagnosis and the targeted nature of treatment.
CN115980365BActive Publication Date: 2026-07-21SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT)
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT)
- Filing Date
- 2023-01-19
- Publication Date
- 2026-07-21
Smart Images
Figure CN115980365B_ABST
Abstract
The present application relates to a kind of anxiety depression plasma biomarker kit detection method, for detecting the plasma biomarker of anxiety depression.The present application provides a kind of application method by detecting plasma interleukin 17 receptor A (Interleukin-17 receptor A, IL-17RA, also known as IL-17R) protein as the application method of anxiety depression biomarker, the method of the present application is used for the subtype classification diagnosis of anxiety depression for non-diagnostic purposes, improve the sensitivity and specificity of anxiety depression screening.
Need to check novelty before this filing date? Find Prior Art